Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit

Experimental Eye Research

Volumn 97, Issue 1, 2012, Pages 154-159

  Li, Hong ^a,b   Lei, Ning ^c,d   Zhang, Ming ^c   Li, Yue ^b   Xiao, Haibo ^c   Hao, Xiaofeng ^b  

^a CHENGDU MEDICAL COLLEGE   (China)

^b Chengdu Kanghong Biotechnology Co Ltd   (China)

^c SICHUAN UNIVERSITY   (China)

^d CHENGDU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Age related macular degeneration; Conbercept; Intravitreal injection; Pharmacokinetics; Vascular endothelial growth factor

Indexed keywords

CONBERCEPT; KH 902; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERANCE; IMMUNE RESPONSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANGIOGENESIS INHIBITORS; ANIMALS; AUTOANTIBODIES; BIOLOGICAL AVAILABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTRAVITREAL INJECTIONS; MALE; RABBITS; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84862802697     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.09.002     Document Type: Article

References (12)

1. Do D.V., Nguyen Q.D., Shah S.M., Browning D.J., Haller J.A., Chu K., Yang K., Cedarbaum J.M., Vitti R.L., Ingerman A., Campochiaro P.A. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br. J. Ophthalmol. 2009, 93:144-149.
2. Ferrara N., Chen H., Davis-Smyth T., Gerber H.P., Nguyen T.N., Peers D., Chisholm V., Hillan K.J., Schwall R.H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 1998, 4:336-340.
3. Gasteiger E.H.C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A. Protein identification and analysis tools on the ExPASy server. The Proteomics Protocols Handbook 2005, 571-607. Humana Press. J.M. Walker (Ed.).
4. Gerber H.P., Kowalski J., Sherman D., Eberhard D.A., Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000, 60:6253-6258.
5. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U S A 2002, 99:11393-11398.
6. Huang J., Frischer J.S., Serur A., Kadenhe A., Yokoi A., McCrudden K.W., New T., O'Toole K., Zabski S., Rudge J.S., Holash J., Yancopoulos G.D., Yamashiro D.J., Kandel J.J. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. U S A 2003, 100:7785-7790.
7. Ruch C., Skiniotis G., Steinmetz M.O., Walz T., Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct. Mol. Biol. 2007, 14:249-250.
8. Saishin Y., Saishin Y., Takahashi K., Lima e Silva R., Hylton D., Rudge J.S., Wiegand S.J., Campochiaro P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell Physiol. 2003, 195:241-248.
9. Suto K., Yamazaki Y., Morita T., Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J. Biol. Chem. 2005, 280:2126-2131.
10. Wong T.Y., Liew G., Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007, 370:204-206.
11. Zhang M., Yu D., Yang C., Xia Q., Li W., Liu B., Li H. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm. Res. 2009, 26:204-210.
12. Zhang M., Zhang J., Yan M., Li H., Yang C., Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol. Vis. 2008, 14:37-49.